Delta Sleep-Inducing Peptide (DSIP)
CognitiveSleep / neuropeptide researchExperimental
Nonapeptide isolated as a putative sleep-promoting factor. Human results are inconsistent; not FDA-approved.
For research use only.
Key Facts
- CAS
- 62568-57-4
- Molecular Weight (MW)
- 848.81 g/mol
- Half-life
- ~7-15 minutes
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Nightly
- Last updated
- 8/23/2026
- Targets
- Sleep-regulatory networks (proposed)
Overview
Nonapeptide isolated as a putative sleep-promoting factor. Human results are inconsistent; not FDA-approved.
Protocol
- Dosage Range
- 100-400 mcg
- Frequency
- Nightly
- Cycle
- 6-12 weeks on, 4-8 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 3 mL BAC for 5 mg vial
Science
Mechanism of Action
Proposed to modulate GABAergic and circadian sleep architecture; blood–brain penetration and physiologic role remain debated.
Targets
Sleep-regulatory networks (proposed)
Studies
- DSIP sleep research review— Journal/year not available
Benefits
Sleep-architecture research tool
Potential Side Effects
- Headache
- Vivid dreams (anecdotal)
- Unknown chronic safety
References
- PMID 3883456External link · Year —